SCHEMBL1463536

SCHEMBL1463536

O=C(O)C(=O)Oc1ccc(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
ELANE P08246 4/20 0.46
CPT1B Q92523 1/20 0.44
LTA4H P09960 1/20 0.44
NR1H2 P55055 1/20 0.44
BAX Q07812 1/20 0.44
GAA P10253 3/20 0.44
MAPT P10636 2/20 0.44
XBP1 P17861 1/20 0.44
P4HB P07237 1/20 0.43
HTT P42858 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
THRB P10828 1/20 0.43
BLM P54132 1/20 0.43
CASP6 P55212 1/20 0.43
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10356467 0.87 ESR2 (0.52) MEN1KMT2AESR1ESR2ELANE
Ammonia Solution, Strong SCHEMBL20819414 0.87 ELANE (0.42) MEN1KMT2AELANEGAAMAPT
Phenol SCHEMBL27489897 0.86 TDP1 (0.48) KMT2AESR1ESR2ELANELTA4H
SCHEMBL10782092 0.82 ELANE (0.44) MEN1KMT2AESR1ESR2ELANE
SCHEMBL419381 0.80 TDP1 (0.50) ELANEMAPTKDM4ETDP1
Hydroquinone SCHEMBL4313659 0.80 ELANE (0.53) MEN1KMT2AESR1ESR2ELANE
SCHEMBL308379 0.80 ELANE (0.53) MEN1KMT2AESR1ESR2ELANE
Methacrylic Acid SCHEMBL8512987 0.80 ELANE (0.60) MEN1KMT2AESR1ESR2ELANE
SCHEMBL24361156 0.79 TPMT (0.44) ELANECA12CA1CA2CA9
SCHEMBL17266582 0.79 KMT2A (0.43) KMT2AKDM4ETDP1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158578-B2 Methods for treating neurological deficits NEUROREPAIR, INC. (US) 2012-04-17 US disclosed
US-20110071078-A1 METHODS FOR TREATING NEUROLOGICAL DEFICITS REID JAMES STEVEN 2011-03-24 US disclosed
US-7790669-B1 Methods for treating neurological deficits by intrastriatal administration of transforming growth factor alpha (TGF-α) NEUROREPAIR, INC. (US) 2010-09-07 US disclosed
EP-0996456-A4 METHODS FOR TREATING NEUROLOGICAL DEFICITS UNIV CALIFORNIA (US) 2003-07-09 EP disclosed
WO-2002049663-A2 COMPOSITIONS AND METHODS FOR MANIPULATING GLIAL PROGENITOR CELLS AND TREATING NEUROLOGICAL DEFICITS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-06-27 WO disclosed
US-20020004039-A1 Methods for treating neurological deficits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION 2002-01-10 US disclosed
US-20010007657-A1 Compositions and methods for manipulating glial progenitor cells and treating neurological deficits NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-07-12 US disclosed
CN-1273534-A Method for treating neurological deficits REGENETS OF THE UNIV OF CALIFO (US) 2000-11-15 CN disclosed
EP-0996456-A1 METHODS FOR TREATING NEUROLOGICAL DEFICITS The Regents of the University of California (US) 2000-05-03 EP disclosed
WO-1999006060-A1 METHODS FOR TREATING NEUROLOGICAL DEFICITS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-02-11 WO disclosed